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Abstract Protein kinases C (PKC) are serine/threonine kinase
enzymes involved in the mechanism of cell survival. Their
pseudosubstrate sequences are autoinhibitory domains, which
maintain the enzyme in an inactive state in the absence of
allosteric activators, thus representing an attractive tool for the
modulation of different PKC isoforms. Here, we report the use of
palmitoylated modified PKC-K, -O, and -j pseudosubstrate
peptides, and determine their intracellular distribution together
with their respective PKC isoenzymes. Finally, we propose that
the differential distribution of the peptides is correlated with a
selective induction of apoptosis and therefore argues for different
involvement of PKC isoforms in the anti-apoptotic program.
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1. Introduction
Protein kinases C (PKCs) are a family of enzymes with
serine/threonine kinase activities. They were originally identi-
¢ed as cytoplasmic, calcium-activated, phospholipid-depend-
ent enzymes [1]. Members of this enzyme family have been
classi¢ed into three groups with respect to their allosteric ac-
tivators (reviewed in [2]). The conventional PKCs (cPKCs) K,
LI, LII, and Q require negatively charged phospholipids, dia-
cylglycerol or phorbol esters and calcium for optimal activa-
tion; the novel PKCs (nPKCs) N, O, a, R, and W require neg-
atively charged phospholipids, diacylglycerol or phorbol
esters, but not calcium; and the atypical PKCs (aPKCs) V/S
and j require only negatively charged phospholipids but not
calcium, diacylglycerol or phorbol esters.
Di¡erent PKC isoenzymes exhibit a distinct tissue distribu-
tion, are activated or inactivated in speci¢c cell compartments
by various lipid metabolites, interact with di¡erent proteins
[3^7] and phosphorylate di¡erent substrates which ultimately
induce di¡erent biological responses [8,9]. PKC is known to
play an important role in processes relevant to neoplastic
transformation, carcinogenesis and tumor cell invasion. More-
over, among other protein kinases and phosphatases, a key
role is indicated for the PKC family in apoptosis.
Apoptosis, or programmed cell death, is a cellular event
which underlies a wide variety of normal physiological phe-
nomena, including morphogenesis and limb development [10],
clonal selection of lymphocytes [11], and safe removal of in-
£ammatory tissue cells [12]. Knowledge about the role of each
PKC isoenzyme in cell survival mechanisms is both limited
and controversial [13,14].
In common with other serine/threonine protein kinases,
PKC isoenzymes contain an autoinhibitory domain at the
N-terminus, in which a short substrate-like peptide, called
the pseudosubstrate, binds to the protein-substrate binding
region, thus maintaining the enzyme in an inactive state in
the absence of allosteric activators [15,16]. These pseudosub-
strate sequences appear to be an attractive tool allowing for
selective inhibition of di¡erent PKC isoenzymes. Recent ap-
proaches [17,18], using the myristoylated pseudosubstrate se-
quence of PKC-K/L, described the modulation of the isoen-
zyme in a cellular model. In two previous reports we have also
described the use of lipid modi¢ed PKC-K/L pseudosubstrates
to modulate, in vitro, the phosphorylation of the puri¢ed
enzyme [19], and the biological activities related to PKC acti-
vation or inhibition [19,20]. In these studies [19,20], biological
activities of PKC-K/L pseudosubstrates on intact cells were
restricted to lipid modi¢ed pseudosubstrate sequences, sug-
gesting an intracellular delivery of the lipopeptide. In the lat-
ter report [20], we demonstrated that an N-terminal NO-free
palmitoyl-lysine-PKC-K/L pseudosubstrate was optimal for
providing cytoplasmic delivery of the biologically active lipo-
peptide. The functionality of the PKC-K/L pseudosubstrate
lipopeptide was assessed through the induction of apoptosis
in treated cells implying that PKCK/L is involved in cell sur-
vival.
In the present report, we used N-terminal palmitoylated
PKC pseudosubstrates, designed from the pseudosubstrate se-
quences of PKC-K, -O, and -j, and investigated their cytoplas-
mic delivery and their ability to selectively modulate their
corresponding PKC isoenzymes, by evaluating these PKC
pseudosubstrate lipopeptides on puri¢ed PKC-K, -O, and -j
in an in vitro enzymatic assay. We also studied the intracel-
lular distribution of the three isoenzymes and their PKC pseu-
dosubstrate lipopeptides in intact cells. Finally, we analyzed
the biological relevance of the cytoplasmic delivery of the
pseudosubstrate lipopeptides by quantifying their implication
in the induction of apoptosis in two di¡erent human cell lines.
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2. Materials and methods
2.1. Peptide and lipopeptide synthesis and characterization
We synthesized the lipopeptides K(Pam)DVANRFARKGALRQ,
K(Pam)ERMNRPKRQGAVRRRV and K(Pam)SIYRRGARRWR-
KL, derived respectively from the PKC-K, -O and -j pseudosubstrate
sequences, modi¢ed in the N-terminal position by the addition of a
NO-palmitoyl-lysine residue. A control ‘scrambled’ lipopeptide, K-
(Pam)ASGRLKWRYRRIR, was designed from the PKC-j pseudo-
substrate sequence. All lipopeptides were synthesized by the solid-
phase method [21] in an automated peptide synthesizer (Applied Bio-
systems, Model 430A, Foster City, CA, USA) using a standard t-
butyloxycarbonyl Boc-benzyl strategy as previously described [19].
Boc-protected amino acids were purchased from Propeptide (Vert-
Le-Petit, France). Boc-L-lysine(Fmoc) was purchased from Novabio-
chem (EMA, Meudon, France). Labelled lipopeptide analogs were
obtained by addition of a biotin (Sigma, St. Louis, MO, USA), in-
troduced at the N-terminal position before ¢nal deprotection with
hydrogen £uoride and cleavage from the resin. All compounds were
puri¢ed by RP-HPLC (Vydac C4 column), checked for homogeneity
by RP-HPLC and capillary electrophoresis and were more than 98.5%
pure in both systems. They were checked for identity by mass spec-
trometry (Bio Ion AB, Uppsala, Sweden). PKC-K pseudosubstrate
lipopeptide [MH] calc. 1967.4, obs. 1968.3; PKC-O pseudosubstrate
lipopeptide [MH] calc. 2417.6, obs. 2417.6; PKC-j pseudosubstrate
lipopeptide [MH] calc. 2084.6, obs. 2085.2; scrambled lipopeptide
[MH] calc. 2084.6, obs. 2083.9.
2.2. In vitro PKC assay
Partially puri¢ed recombinant PKC [22] was incubated in a 96 well
polystyrene plate in a total volume of 120 Wl in the absence or pres-
ence of phosphatidylserine (50 WM) plus PMA (1 WM, for PKC-K and
-O) diluted in bu¡er containing 25 mM Tris-HCl (pH 7.0), 3 mM
MgCl2, 0.1 mM ATP, 0.5 mM EDTA, 1 mM EGTA, 2 mM CaCl
and 5 mM 2-mercaptoethanol; and in the presence or absence of the
speci¢ed peptides. After a 30 min pre-incubation period at 30‡C, the
reaction was started by spotting a 100 Wl of the reaction mixture onto
a 96 well substrate-coated plate (Panvera, Madison, WI, USA). The
reaction was carried out for 10 min at 30‡C.
The amount of phosphorylated substrate was determined by ELISA
using a biotinylated monoclonal antibody which recognizes the phos-
phorylated form of the peptide, according to the manufacturer’s pro-
tocol (Panvera).
2.3. Cell culture
Jurkat and HL60 human cell lines were maintained in RPMI 1640
supplemented with 10% fetal calf serum (FCS, Gibco), 2 mM gluta-
mine (Sigma), 1 mM sodium pyruvate (Sigma), 100 U/ml penicillin
and 100 Wg/ml streptomycin under 5% CO2 at 37‡C.
2.4. Immuno£uorescent labelling
The subcellular localization of PKC isoenzymes and the intracellu-
lar delivery of PKC pseudosubstrate lipopeptides was assessed using
indirect immuno£uorescence staining and confocal microscopy.
Mouse monoclonal antibodies directed against PKC-K, -O or -j were
purchased from Transduction Laboratories Inc. (Lexington, KY,
USA). Monoclonal goat anti-mouse IgG coupled to Alexa 568, strep-
tavidin conjugated to Alexa 488 and TO-PRO-3 iodide were pur-
chased from Molecular Probes (Leiden, The Netherlands).
Cells (1U106) were incubated for 10 min at 37‡C with 5 WM of
di¡erent biotinylated PKC pseudosubstrate lipopeptides. Cells were
washed twice with PBS and then ¢xed with PBS containing 2.5%
paraformaldehyde, 0.01% glutaraldehyde for 30 min at room temper-
ature. Fixed cells were placed on glass coverslips, permeabilized with
0.05% saponin in PBS for 10 min and blocked for 10 min at room
temperature in permeabilizing bu¡er (PBS containing 2% BSA and
0.05% saponin). Then, cells were incubated for 1 h at 37‡C with
primary antibodies (mouse anti-PKC-K, -O or -j) used at 1:50 dilution
(5 Wg/ml) in permeabilizing bu¡er. After ¢ve washes with permeabili-
zing bu¡er, cells were incubated with both the secondary antibody, a
monoclonal goat anti-mouse IgG coupled to Alexa 568 used at a
1:100 dilution (2 Wg/ml) and streptavidin-Alexa 488 conjugate used
at 1:100 dilution in permeabilizing bu¡er. Cells were washed twice
with permeabilizing bu¡er and twice with PBS-2% BSA and then,
nuclear DNA was stained with TO-PRO-3 iodide (0.1 WM) for 45
min at 37‡C.
Slides were mounted using Vectashield (Vector Laboratories, Com-
pie'gne, France).
2.5. Confocal microscopy
Fluorescence-stained slides were examined under a Leica TCS NT
laser scanning confocal microscope (Leica, Heidelberg, Germany)
comprising a krypton/argon laser (488, 568, and 647 nm excitations
are possible). Simultaneous three channel recording was performed.
Frame scanning was performed at U1000 magni¢cation and a single
optical section was collected per ¢eld.
2.6. Detection of apoptosis in Jurkat and HL60 cell lines by TUNEL
(terminal deoxynucleotidyl transferase dUTP nick-end labelling)
Jurkat or HL60 cell lines (2U106 cells) were resuspended in FCS-
free medium. Cells were incubated for 6 h with di¡erent concentra-
tions of either PKC-K, -O, or -j pseudosubstrate lipopeptides. After
three washes with PBS-BSA 1%, cells were ¢xed in PBS-paraformal-
dehyde 4% for 1 h on ice. Apoptotic cells were detected with the
Apoptosis Detection System (Promega, Madison, WI, USA). Brie£y,
cells were resuspended in 70% ice-cold ethanol solution and stored
overnight at 320‡C. Samples were labelled with TdT bu¡er according
to the manufacturer’s instructions. Reactions were terminated by add-
ing EDTA. Cells were analyzed by £ow cytometry (Elite Epics II,
Coulter, Hialeah, FL, USA) for the amount of £uorescein-12-
dUTP. In order to identify both apoptotic and non-apoptotic events,
cells were resuspended in propidium iodide solution (diluted to 5 Wg/
ml in PBS) and analyzed by £ow cytometry.
3. Results
3.1. E¡ects of palmitoylated PKC pseudosubstrate lipopeptides
on the phosphorylation of their isoenzymes
PKC-K, -O and -j pseudosubstrate lipopeptides were as-
sessed for their ability to inhibit the activity of the puri¢ed
recombinant PKC-K, -O or -j. Only inhibition of PKC-j was
selective for its pseudosubstrate (Fig. 1). A clear dose-depen-
dent inhibitory e¡ect was observed with the PKC-j pseudo-
substrate lipopeptide (IC50 : 0.3 WM), while neither the
scrambled lipopeptide nor the PKC-K or PKC-O pseudosub-
strate lipopeptides exhibited inhibitory activity upon puri¢ed
recombinant PKC-j. Inhibition of the puri¢ed recombinant
PKC-K or PKC-O was observed with all three palmitoylated
pseudosubstrate lipopeptides, revealing no selectivity for the
PKC isoenzymes (data not shown). Since cell-free systems do
not contain crucial components relevant to the phenomenon
under study, we elected to review the selectivity of each pal-
mitoylated pseudosubstrate lipopeptide in assays to be per-
formed on intact cells.
3.2. Expression and subcellular localization of PKC isoenzymes
The expression and the subcellular localization of PKC-K,
-O and -j in Jurkat cell line was determined by confocal mi-
croscopy (Fig. 2) using monoclonal antibodies directed against
PKC-K, -O or -j and showed a cytoplasmic expression for all
three isoenzymes. However, the subcellular localization of
each isoenzyme was di¡erent. Antibodies directed against
PKC-K revealed high intensity cytoplasmic staining in close
proximity to the plasma membrane. This staining was not
di¡use but localized in clusters (Fig. 2A). In contrast, the
immunostaining of PKC-j showed a uniform and di¡use cy-
toplasmic labelling (Fig. 2E). The identical feature of cellular
distribution was observed for PKC-O (data not shown). No
nuclear expression was detected for the three PKC isoen-
zymes.
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3.3. Intracellular delivery of PKC pseudosubstrate lipopeptides
and colocalization with their respective PKC isoenzymes
To address the intracellular delivery of the pseudosubstrate
lipopeptides and their respective cellular localization, we used
the pseudosubstrate lipopeptides of each isoenzyme, modi¢ed
at their N-terminus by a biotin group.
The intracellular localization of the biotinylated lipopep-
tides was proven since the cells needed to be permeabilized
before Alexa 488-streptavidin treatment in order to achieve
£uorescent labelling. No £uorescence was observed in cells
that were not permeabilized (data not shown). This observa-
tion dismisses the possibility that the lipopeptide was an-
chored to the extracellular part of the cell membrane. The
internalization of lipopeptides occurs rapidly, since following
a 10 min incubation, lipopeptides were observed in the cells
(Fig. 2B,F). Furthermore, this cytoplasmic delivery does not
require endocytosis, as a 4‡C incubation does not a¡ect the
observed cytoplasmic delivery (data not shown).
When cells were incubated with the biotinylated PKC-K, -O
or -j pseudosubstrate lipopeptides, and then stained with
monoclonal antibodies directed against the same PKC iso-
forms, an overlapping signal was observed. Indeed, Jurkat
cells incubated with PKC-K biotinylated pseudosubstrate lipo-
peptide, then stained with a monoclonal antibody directed
against PKC-K, exhibited an overlapping signal characterized
by intracellular clusters near the plasma membrane, attesting
to a colocalization of the lipopeptide and its de¢ned target
(Fig. 2D). In addition, when Jurkat cells were incubated with
PKC-j biotinylated pseudosubstrate lipopeptide, then stained
with a monoclonal antibody directed against PKC-j, the over-
lapping signal was di¡use in the cytoplasm, following the
subcellular localization of the PKC isoenzyme (Fig. 2H). A
similar pattern of colocalization was observed with cells incu-
bated with PKC-O biotinylated pseudosubstrate lipopeptide,
and then stained with a monoclonal antibody directed against
PKC-O (data not shown).
Fig. 2. Confocal microscopy study of the cellular distribution of PKC-K and -j isoenzymes together with their respective pseudosubstrate lipo-
peptides. PKC isoenzymes were detected by indirect immunochemistry using a monoclonal antibody against PKC-K or -j and a goat anti-
mouse Alexa 568 conjugated as secondary antibody (A and E). Cellular localization of biotinylated lipopeptides was revealed with Alexa 488-
streptavidin (B and F). Nuclear DNA was stained with TO-PRO-3 iodide (C and G). Triple exposure (D and H) show the overlapping £uores-
cence of the di¡erent pseudosubstrate lipopeptides and their respective PKC isoenzymes. Magni¢cation: U1000. Bar equals 5 Wm.
Fig. 1. Inhibition of kinase activity of puri¢ed recombinant PKC-j incubated with either PKC-K/L (E), -O (b) or -j (a) pseudosubstrate lipo-
peptides or scrambled pseudosubstrate lipopeptide (R). Mean of percentage of inhibition þ S.E.M. (n = 4).
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3.4. E¡ect of di¡erent PKC isoenzyme pseudosubstrate
lipopeptides on apoptosis
We next wanted to assess the biological functionality of the
pseudosubstrate lipopeptides. In a previous report [20] we
described that treatment of several human cell lines with 50
WM of PKC-K/L pseudosubstrate lipopeptide resulted in the
induction of apoptosis. Since a key role is indicated for PKC
in the mechanism of apoptosis, we decided to investigate the
potential e¡ect of PKC-K, -O or -j pseudosubstrate lipopep-
tides upon the induction of apoptosis in human cells. Apop-
tosis in treated cells was qualitatively observed by DNA frag-
mentation (data not shown) and quanti¢ed by £ow cytometry
(Fig. 3). Jurkat cells incubated with di¡erent concentrations of
either PKC-O or -j pseudosubstrate lipopeptides for 6 h, ex-
hibited an increase of apoptosis in a dose-dependent manner
(Fig. 3A). This induction of apoptosis was not related to
palmitic acid since the control scrambled lipopeptide did not
exhibit such an e¡ect. Furthermore, this induction of apopto-
sis was dependent upon the pseudosubstrate sequence as
PKC-K/L pseudosubstrate lipopeptide or scrambled lipopep-
tide did not lead to a signi¢cant induction of apoptosis. A
similar study performed on the HL60 cell line (Fig. 3B) re-
vealed a greater sensitivity of these cells to apoptosis, since
apoptosis was induced by lower concentrations (5 WM) of
PKC-O or -j pseudosubstrate, whereas neither the PKC-K/L
pseudosubstrate lipopeptide nor the scrambled lipopeptide
showed comparable e¡ects. In this cellular assay the induction
of apoptosis induced by either PKC-O or -j pseudosubstrate
was remarkable starting at 5 WM, and increasing in a dose-
dependent manner.
4. Discussion
In a previous report [19] we showed that palmitic modi¢-
cation of PKC-K/L pseudosubstrate increased the ability of
the pseudosubstrate to inhibit the phosphorylation of the cor-
responding PKC isoenzymes. Moreover, we reported [19,20]
that incubation of intact cells with PKC-K/L pseudosubstrate
lipopeptide led to the inhibition of biological activities known
to be mediated by PKCs, whereas the non-lipidic PKC-K/L
pseudosubstrate did not exhibit similar e¡ects suggesting an
intracellular delivery of the lipopeptide. Thus, we decided to
modify PKC-K/L, -O, -j pseudosubstrate sequences with a pal-
mitic moiety in order to allow their cytoplasmic delivery and
to investigate their implication in the induction of apoptosis.
In an attempt to evaluate the inhibitory activity of each
pseudosubstrate lipopeptide with its respective puri¢ed isoen-
zyme, we studied their ability to inhibit kinase activity in a
cell-free enzyme assay. Only PKC-j was selectively inhibited,
in a dose-dependent manner, by its pseudosubstrate lipopep-
tide. Since Zoukhri et al. [23] reported that no selectivity of
PKC pseudosubstrate sequences was observed in a cell-free
system, while results obtained in cellular assay argue in favor
of the selective inhibition of PKC isoenzymes, we decided to
investigate the e⁄ciency of the di¡erent pseudosubstrate lipo-
peptides to modulate the activity of their corresponding iso-
enzymes in a cellular assay.
First, we clearly established the intracellular delivery of the
palmitoyl modi¢ed pseudosubstrate of three di¡erent PKC
isoenzymes: PKC-K, -O and -j. We determined by confocal
microscopy the subcellular localization of the three PKCs iso-
enzymes in the Jurkat cell line. Then, we investigated the
cellular distribution of di¡erent PKC pseudosubstrate lipo-
peptides. We found that PKC-K pseudosubstrate lipopeptide
was located intracellularly near the cell membrane and double
staining revealed its colocalization with PKC-K. The same
experiments performed with PKC-j and -O pseudosubstrate
lipopeptides revealed a di¡use cytosolic distribution of the
two lipopeptides which corresponded to their respective
PKC isoenzymes. These results con¢rmed the di¡erent subcel-
lular localization of PKC isoenzymes as previously reported
[24]. When we studied the distribution of PKC-j with PKC-K
pseudosubstrate lipopeptide, the latter was always observed in
proximity to the inner surface of the cell membrane, where its
de¢ned target is localized. Nevertheless, since localization of
the PKC-j is di¡use into the cytoplasm, double exposure ob-
servation reveals a weak overlapping signal adjacent to the
cell membrane (data not shown). The same feature of obser-
vation was obtained when we examined the distribution of
Fig. 3. Quanti¢cation of apoptosis induced on Jurkat cells (A) and
HL-60 cells (B) incubated for 6 h with either PKC-K/L (E), -O (b)
or -j (a) pseudosubstrate lipopeptides or scrambled pseudosubstrate
lipopeptide (R). Apoptosis was quanti¢ed by £ow cytometry analy-
sis using the TUNEL methodology. Results are representative of
three independent experiments.
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PKC-O with PKC-K pseudosubstrate lipopeptide, since PKC-O
is also di¡used into the cytoplasm [24].
Since PKCs play a key role in apoptosis, the modulation of
di¡erent isoenzymes was evaluated through the quanti¢cation
of apoptosis in cells treated with PKC-K, -O and -j pseudo-
substrate lipopeptides. Induction of apoptosis was clearly de-
pendent upon the pseudosubstrate sequence, attesting to a
selective e¡ect on apoptosis for each PKC isoenzyme. Indeed,
the human T cell line (Jurkat) showed a greater sensitivity to
apoptosis induced by PKC-j pseudosubstrate and a reduced
sensitivity to PKC-O pseudosubstrate lipopeptide, whereas the
same concentrations (5 WM, 10 WM) of PKC-K/L pseudosub-
strate lipopeptide did not induce programmed cell death. The
human leukemia cell line (HL-60) was highly sensitive to
apoptosis induced by PKC-O pseudosubstrate lipopeptide
and to a lesser extent the PKC-j pseudosubstrate lipopeptide.
Neither PKC-K/L pseudosubstrate lipopeptide nor scrambled
control lipopeptide exhibited comparable biological activities.
Taken together these results suggest a selective activity of
PKC pseudosubstrates which might be related to a similar
selective action on their respective isoenzyme. These data dis-
miss the results obtained in a cell-free assay where PKC pseu-
dosubstrate lipopeptides were evaluated for their ability to
selectively inhibit the activity of their respective isoenzyme.
Indeed, the results obtained established that puri¢ed recombi-
nant PKC-j was the only isoenzyme found to be selectively
inhibited by its pseudosubstrate. Based upon the cell-free as-
say, one would expect that in intact cells, a co-localization
PKC-K/L pseudosubstrate with either PKC-K and -O isoen-
zymes would be observed. However, the colocalization of
the lipopeptide was clearly associated with the distribution
of its target (PKC-K). Moreover, when human cells were in-
cubated with 5 WM of palmitoylated PKC-j pseudosubstrate
plus 5 WM of palmitoylated PKC-O pseudosubstrate, the apop-
tosis observed was not comparable to that induced by 10 WM
of either PKC-j or -O pseudosubstrate, but was similar to that
induced by 5 WM of each lipopeptide (data not shown). The
discrepancy in the selectivity observed between the cellular
assay and the cell-free assay might be related to the absence
of some crucial components for the phenomenon under study.
Indeed, increasing evidence suggests that part of the speci¢city
of action of PKC isoenzymes might be conferred by their
association with speci¢c proteins that target them to speci¢c
intracellular compartments [8,25^28]. Moreover, our results
concerning the induction of apoptosis by PKC-O and PKC-j
pseudosubstrate lipopeptides con¢rmed previous reports
where these two isoenzymes were involved in cell survival
mechanisms. Pongracz et al. [29] indicated that the expression
of speci¢c PKC isoenzymes is modulated during apoptosis
and that PKC-L and PKC-j may play speci¢c roles in the
regulation of the apoptotic program. The latter isoenzyme
has been identi¢ed to be closely involved in anti-apoptotic
processes [30^33]. PKC-O is also reported to be a reducer of
apoptosis [34] and a putative oncogene [35,36]. Recently
Mayne et al. [37] showed that PKC-O is required for the pro-
tective e¡ect of TPA in tumor necrosis factor K-induced apop-
tosis suggesting that PKC-O may play an important role in
leukemia cell survival. On the other hand, Gubina et al. [38]
reported that overexpression of PKC-O in an interleukin-3-
dependent human cell prolonged cell survival in the absence
of the cytokine and resulted in an induction of bcl-2 expres-
sion. All these data converge with our observations concern-
ing the induction of apoptosis with PKC-O and PKC-j pseu-
dosubstrate lipopeptide-treated cells. Taken together with the
colocalization of these pseudosubstrates and their speci¢c tar-
gets, our work strengthens the hypothesis that the two isoen-
zymes are involved in cell survival mechanisms. Implication of
PKC-K in an anti-apoptotic mechanism seems to be of less
importance, since at the concentrations used its pseudosub-
strate lipopeptide did not induce apoptosis but higher concen-
trations of PKC-K pseudosubstrate lipopeptide led to a spe-
ci¢c induction of apoptosis as previously described [20]. These
data argue in favor of a di¡erential implication of the three
PKC isoenzymes in the control of apoptosis.
Besides the modulation of PKC isoenzymes, our work em-
phasizes the use of lipopeptides to modulate cellular activities
through an interaction with intracytoplasmic targets. Indeed,
the ability of lipopeptides to be intracellularly delivered while
remaining biologically active gives rise to new opportunities.
In fact, in other reports [39,40] we described the synthesis of a
lipopeptide agonist toward interferon-Q receptor. These syn-
thetic agonists of a cytokine were able to reproduce the activ-
ities of the native cytokine, via interaction with the intracel-
lular part of the cytokine receptor. Taken together, these
di¡erent reports [19,20,39,40] emphasize the use of lipopep-
tides as a promising new approach for the pharmacomodula-
tion of intracellular targets.
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